<DOC>
	<DOC>NCT02872714</DOC>
	<brief_summary>The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<criteria>Histologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from ureters, upper tract, renal pelvis, and bladder. Eastern Cooperative Oncology Group (ECOG) performance status of 02. Life expectancy â‰¥ 12 weeks. Radiographically measurable or evaluable disease per RECIST v1.1. Known FGF/FGFR alteration from the sponsor's central laboratory and have either 1) failed at least 1 previous treatment for their metastatic or surgically unresectable urothelial carcinoma (ie, chemotherapy, immunotherapy) or 2) are platinum ineligible. Prior receipt of a selective FGFR inhibitor. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half lives (whichever is shorter) before the first dose of study drug. Inability or unwillingness to swallow INCB054828 or significant gastrointestinal disorder(s) that could interfere with the absorption, metabolism, or excretion of INCB054828.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Urothelial carcinoma</keyword>
	<keyword>fibroblast growth factor (FGF)</keyword>
	<keyword>fibroblast growth factor receptor (FGFR)</keyword>
	<keyword>FGF/FGFR alterations</keyword>
</DOC>